Day traders' weekend lounge May 6 - 8, page-35 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Originally posted by mirren: ↑

It always interested me that from my understanding back then the virus could be eradicated from the reservoir cells - is the objective of the drug -
I think the excitement back then was the fact that they thought it could do this -
The massive volumes that were traded back then in comparison to the SOI - is still huge 3.5 billion in 2 months - that was not a small little group of traders that traded all that volume... of course it spiked up to three times the price of where it landed - and trapped a lot of people - which since then has been absorbing that supply I assume - It can go along for another long while here until it proves it can achieve what it asserts-re the chart
- Just a question - where are the trials up to in the phases they need to go through >? My understanding is that human trials need to get to phase three and prove their worth there -
the mouse trials for the covid virus would need to progress to human trials >>?
So the chart is saying to me that it is trying to break that resistance level here - if it does this - I expect a rise to the upper resistance and a retest of the break - certainly worth assessing the time lines and keeping an eye on the chart and volume from here -
As with all biotech's it is difficult to understand where they are up to and how much chance they have of proving they work - explaining that in a way a lay person can grasp the potential but importantly the timeline is the difficult part - so often these things take a long time from discovery to end game - but certainly of interest - if it works it will be great.

Expand

Hi mirren

HIV: since the 2018 great spike, Biotron have been mostly trying to identify the mode of action of BIT225. Having great results - clearing macrophage reservoir cells- was a great achievement, but not knowing exactly how slowed further progress. That hurdle was overcome 2021 and three new trials commenced with more precise end points that will certainly put 225 in a better place for entry to phase 3. As you know, phase 3 never occurs unless all boxes are ticked. Australian trials with St Vincents and one in Thailand. Initial results not coming until later this year. It is worth mentioning that the research they've done in the last two years was published and now creates the backbone to further development ie phase 3. Naturally, it won't occur until the new trials are near complete, so next year.

Covid19.

yes, only animal trials to date, but that is about to change very soon when (if) entering CTAP. As far as drug developments go, like the covid vaccine development, its happening at lightning speed. These very successful mice trials have proven several things: non progression of C19 disease; and very importantly, non progression of disease when drug candidate given after disease onset. This is a first for all drugs being used to treat C19 (albeit in mice only so far).

The CTAP notice is imminent, and if successful, all I can say is that traders don't want to be caught not holding, at least not for long.......

Entering CTAP is only the first stage of this new era, and will cause a paradigm shift for Biotron (if) when it goes ahead. The results of CTAP of course is what will make or brake us as far as C19 goes. CTAP ha sonly approved one drug so far for treating C19, Paxlovid, by Pfizer. However, not all is rosy with this new wonder drug.
https://abcnews.go.com/Health/scientists-investigate-perplexing-viral-rebound-covid-19-cases/story?id=84475465

Considering BIT225's very high safety profile after nine HIV trials, and with its ability to clear latent HIV virus, any similar results with C19, as it has in the high ACE2 mice, will see it potentially even replacing Paxlovid.

Let's just settle for selling like Paxlovid.

That's the optimistic outcome. The lesser version sees all bats shot from skies.